CA2962117C - Pulmonary administration of pyocins for treating bacterial respiratory infections - Google Patents

Pulmonary administration of pyocins for treating bacterial respiratory infections Download PDF

Info

Publication number
CA2962117C
CA2962117C CA2962117A CA2962117A CA2962117C CA 2962117 C CA2962117 C CA 2962117C CA 2962117 A CA2962117 A CA 2962117A CA 2962117 A CA2962117 A CA 2962117A CA 2962117 C CA2962117 C CA 2962117C
Authority
CA
Canada
Prior art keywords
pyocin
pyocins
type
subject
infection
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2962117A
Other languages
English (en)
French (fr)
Other versions
CA2962117A1 (en
Inventor
Daniel Walker
Laura MCCAUGHEY
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Glasgow
Original Assignee
University of Glasgow
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Glasgow filed Critical University of Glasgow
Publication of CA2962117A1 publication Critical patent/CA2962117A1/en
Application granted granted Critical
Publication of CA2962117C publication Critical patent/CA2962117C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/21—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • AIDS & HIV (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2962117A 2014-09-23 2015-09-22 Pulmonary administration of pyocins for treating bacterial respiratory infections Active CA2962117C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1416788.6A GB201416788D0 (en) 2014-09-23 2014-09-23 Therapeutic applications for pyocins
GB1416788.6 2014-09-23
PCT/EP2015/071768 WO2016046218A1 (en) 2014-09-23 2015-09-22 Pulmonary administration of pyocins for treating bacterial respiratory infections

Publications (2)

Publication Number Publication Date
CA2962117A1 CA2962117A1 (en) 2016-03-31
CA2962117C true CA2962117C (en) 2023-04-25

Family

ID=51869352

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2962117A Active CA2962117C (en) 2014-09-23 2015-09-22 Pulmonary administration of pyocins for treating bacterial respiratory infections

Country Status (7)

Country Link
US (2) US11643442B2 (https=)
EP (1) EP3200813B1 (https=)
JP (1) JP6836506B2 (https=)
CN (1) CN107073073B (https=)
CA (1) CA2962117C (https=)
GB (1) GB201416788D0 (https=)
WO (1) WO2016046218A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11857606B2 (en) 2017-12-14 2024-01-02 Bactoclear Holdings Pte. Ltd. Therapeutic bacteriocins
US20220024992A1 (en) * 2018-11-02 2022-01-27 The Rockefeller University Compositions and methods comprising lysocins as bioengineered antimicrobials for use in targeting gram-negative bacteria
EP3957995A1 (en) * 2018-11-19 2022-02-23 Bioaster Methods and reagents for multiplex binding experiments
MX2021014984A (es) * 2019-06-06 2022-01-24 Nomad Bioscience Gmbh Klebicinas para el control de klebsiella.
EP4248987A1 (en) * 2022-03-21 2023-09-27 Nomad Bioscience GmbH Chimeric bacteriocins and method for the control of pseudomonas
CN121135834A (zh) * 2024-06-14 2025-12-16 无锡佰翱得生物科学股份有限公司 一种绿脓杆菌InA蛋白及其应用
CN121135836A (zh) * 2024-06-14 2025-12-16 无锡佰翱得生物科学股份有限公司 一种绿脓杆菌免疫蛋白及其应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861754A (en) 1986-05-28 1989-08-29 Farkas Himsley Hannah Bacteriocins and compositions thereof in anti-viral treatment
JP3655645B2 (ja) * 1992-02-28 2005-06-02 中外製薬株式会社 経粘膜投与剤
CA2242335A1 (en) 1996-11-15 1998-05-22 Pathogenesis Corporation Pure biologically active colistin, its components and a colistin formulation for treatment of pulmonary infections
CA2381755A1 (en) * 1999-08-26 2001-03-01 Vion Pharmaceuticals, Inc. Compositions and methods for delivery of an agent using attenuated salmonella containing phage
US20060229244A1 (en) * 2004-09-27 2006-10-12 Robert Dorit Engineered bacteriocins and bacteriocin combinations and methods for treating bacterial based infections
ES2387722T3 (es) * 2006-05-15 2012-09-28 Avidbiotics Corporation Bacteriocinas modificadas y métodos para su uso
US7700729B2 (en) * 2006-05-15 2010-04-20 Avidbiotics Corporation Modified bacteriocins and methods for their use
WO2008002663A2 (en) * 2006-06-28 2008-01-03 The Board Of Trustees Of The Leland Stanford Junior University Immunogenic protein constructs
US20080286236A1 (en) * 2007-05-14 2008-11-20 Avidbiotics Corporation Inhibition of yersinia pestis
JP6243325B2 (ja) * 2011-04-12 2017-12-06 ガンガゲン インコーポレーティッド キメラ抗菌ポリペプチド
GB201116234D0 (en) * 2011-09-20 2011-11-02 Aseptika Ltd Biomarkers for respiratory infection

Also Published As

Publication number Publication date
CN107073073A (zh) 2017-08-18
WO2016046218A1 (en) 2016-03-31
GB201416788D0 (en) 2014-11-05
US20230303636A1 (en) 2023-09-28
EP3200813A1 (en) 2017-08-09
CA2962117A1 (en) 2016-03-31
JP6836506B2 (ja) 2021-03-03
US11643442B2 (en) 2023-05-09
EP3200813B1 (en) 2021-04-07
JP2017529398A (ja) 2017-10-05
US12162911B2 (en) 2024-12-10
CN107073073B (zh) 2021-07-09
US20170240602A1 (en) 2017-08-24

Similar Documents

Publication Publication Date Title
US12162911B2 (en) Pulmonary administration of pyocins for treating bacterial respiratory infections
Lee et al. Biology of Acinetobacter baumannii: pathogenesis, antibiotic resistance mechanisms, and prospective treatment options
Waters et al. Cystic fibrosis microbiology: advances in antimicrobial therapy
Huang et al. Immunization with a 22-kDa outer membrane protein elicits protective immunity to multidrug-resistant Acinetobacter baumannii
CN116077630A (zh) 具有对抗革兰氏阴性菌的活性的溶素多肽
JP2024010053A (ja) シュードモナス・エルギノーサに対する殺菌活性を有する溶解素及びその誘導体の特定
Egan et al. Bacteriocins: antibiotics in the age of the microbiome
US11207378B2 (en) Compositions for inhibiting formation of and/or disrupting bacterial biofilms and methods of use therefor
US20220288183A1 (en) Vaccine constructs and uses thereof against staphylococcus infections
WO2014009744A1 (en) Colicins for treating bacterial infections
JP2026031930A (ja) クレブシエラの制御のためのクレビシン
KR20210024005A (ko) 스태필로코커스 아우레우스 및 그람 양성 세균을 항생제에 재민감화시키기 위한 리신 및 이의 유도체
Kang et al. PEP27-2, a potent antimicrobial cell-penetrating peptide, reduces skin abscess formation during Staphylococcus aureus infections in mouse when used in combination with antibiotics
US20220401514A1 (en) Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative and acid-fast bacteria
Gilmore et al. Pathogenesis mediated by bacterial membrane vesicles
US20210330738A1 (en) Antimicrobial, bacteriophage-derived polypeptides and their use against gram-negative bacteria
JP5934225B2 (ja) 抗微生物タンパク質
HK1241754B (en) Pulmonary administration of pyocins for treating bacterial respiratory infections
Sharma et al. Antimicrobial Resistance in Acinetobacter baumannii: A Challenge to Clinical Settings
Romanova et al. Review of alternative antimicrobial therapies
Lee Lee JH, Park M, Park KS, Bae IK, Kim YB, Cha CJ, Jeong BC and Lee SH (2017) Biology of Acinetobacter baumannii: Pathogenesis, Antibiotic Resistance Mechanisms, and Prospective Treatment Options
Paškevičius Development and synthesis of plant-derived recombinant biopharmaceutical proteins active against gram-negative pathogenic bacteria
Amiss Investigating the use of cell-penetrating peptides to target bacteria inside host cells
Lorenzo-Leal et al. Antibacterial Alternatives to a Dying Antibiotic Pipeline
Johnson Escherichia spp.

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200910

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240910

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20240910

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20240910

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250910

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250910